

B C

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**(19) World Intellectual Property Organization
International Bureau**



A standard linear barcode is located at the bottom of the page, spanning most of the width.

**(43) International Publication Date
4 December 2003 (04.12.2003)**

PCT

(10) International Publication Number
WO 03/099792 A1

- (51) **International Patent Classification⁷:** C07D 223/16, A61K 31/55, A61P 25/18, C07D 209/44, 217/02, 217/04 [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).

(21) **International Application Number:** PCT/EP03/05728

(22) **International Filing Date:** 28 May 2003 (28.05.2003)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
0212399.0 29 May 2002 (29.05.2002) GB

(71) **Applicant:** GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) **Inventors; and**

(75) **Inventors/Applicants (for US only):** GRIBBLE, Andrew, Derrick [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). FORBES, Ian, Thomson [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). LIGHTFOOT, Andrew [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). PAYNE, Andrew, H [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue,

(74) **Agent:** MCKINNELL, Denise; GlaxoSmithKline, CN925.1, 980 Great West road, Brentford, Middlesex TW8 9GS (GB).

(81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

 - *with international search report*
 - *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the begin-

Published.

- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS



WO 03/099792 A1

-CO₂C1-6alkyl, -CO₂NR5R6, -SO₂NR5R6, -(CH₂)pNR5R6, -(CH₂)pNR5COR6, optionally substituted aryl ring, optionally substituted heteroaryl ring or optionally substituted heterocyclyl ring; R3 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC1-6alkyl, trifluoromethyl, trifluoromethoxy, C1-6alkyl, C1-6alkoxy, C1-6fluoroalkoxy, -(CH₂)pC3-6cycloalkyl, -(CH₂)pOC3-6cycloalkyl, -COCl-6alkyl, -SO₂C1-6alkyl, -SOC1-6alkyl, -S-C1-6alkyl, -CO₂C1-6alkyl, -CO₂NR7R8, -SO₂NR7R8, -(CH₂)pNR7R8 or -(CH₂)pNR7COR8; R4 represents hydrogen, hydroxy, C1-6alkyl, C1-6alkoxy, C1-6fluoroalkoxy, trifluoromethyl, trifluoromethoxy, halogen, -OSO₂CF₃, -(CH₂)pC3-6cycloalkyl, -(CH₂)qOC1-6alkyl or -(CH₂)pOC3-6cycloalkyl; R5 and R6 each independently represent hydrogen, C1-6alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring; R7 and R8 each independently represent hydrogen or C1-6alkyl; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; q independently represents an integer selected from 1, 2 and 3; or a pharmaceutically acceptable salt or solvate thereof, with the proviso that the compounds 8-hydroxy-3-methyl-7-phenylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 8-hydroxy-7-(hydroxyphenyl)sulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline and 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline hydrochloride are excluded. The compounds are useful in therapy, in particular as antipsychotic agents.

BEST AVAILABLE COPY

7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS
COMPOUNDS

This invention relates to novel compounds, pharmaceutical compositions containing them and their use in therapy, in particular as antipsychotic agents.

5

EP285287 describes 3-benzazepine compounds for use in treating gastrointestinal motility disorders including the compounds 8-hydroxy-3-methyl-7-phenylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine and 8-hydroxy-7-(hydroxyphenyl)sulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

10

J. Med. Chem. 1999, 42, 118-134 and Biorg. Med. Chem. Lett, 1999, 9(3), 481-486 describe 7-substituted-1,2,3,4-tetrahydroisoquinolines and their relative affinities toward phenylethanolamine N-methyltransferase, including the compound 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline and its hydrochloride.

15

International patent applications WO98/06699, WO97/43262 and WO02/40471 (SmithKline Beecham) disclose tetrahydroisoquinoline and tetrahydrobenzazepine derivatives which are selective D3 receptor antagonists and are said to be useful as antipsychotic agents. All of these derivatives possess a group other than hydrogen or 20 alkyl attached to the nitrogen atom of the tetrahydroisoquinoline or tetrahydrobenzazepine ring.

International patent application WO98/12180 (BASF) discloses hetaryl cyclohexanedione derivatives including tetrahydroisoquinoline derivatives that are said to be useful for 25 controlling harmful plants.

International patent application WO02/46164 (AstraZeneca) discloses tetrahydroisoquinoline and isoindoline derivatives that are ER- β -selective ligands and are said to be useful in the treatment or prophylaxis of Alzheimer's disease, anxiety disorders, 30 depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis or prostate cancer.


International patent application WO 01/85695 discloses tetrahydroisoquinoline analogues useful as growth hormone secretagogues. Such analogues are also said to be useful in 35 the treatment of disorders including *inter alia*, obesity, schizophrenia, depression and Alzheimer's disease.

Japanese patent application JP2001/19676 (Takeda) describes the synthesis of tetrahydrobenzazepine derivatives that are said to be useful for increasing cAMP concentration in mammals and, in particular, for treating obesity.

We have now found a novel group of phenylsulfonyl compounds which are useful particularly as antipsychotic agents.

According to the invention, there is provided a compound of formula (I):

5



wherein

- A and B represent the groups $-(CH_2)_m-$ and $-(CH_2)_n-$ respectively;
- R^1 represents hydrogen or C_{1-6} alkyl;
- R^2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxy C_{1-6} alkyl, trifluoromethyl, trifluoromethoxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} fluoroalkoxy, $-(CH_2)_pC_{3-6}$ cycloalkyl, $-(CH_2)_pOC_{3-6}$ cycloalkyl, $-COC_{1-6}$ alkyl, $-SO_2C_{1-6}$ alkyl, $-SOC_{1-6}$ alkyl, $-S-C_{1-6}$ alkyl, $-CO_2C_{1-6}$ alkyl, $-CO_2NR^5R^6$, $-SO_2NR^5R^6$, $-(CH_2)_pNR^5R^6$, $-(CH_2)_pNR^5COR^6$, optionally substituted aryl ring, optionally substituted heteroaryl ring or optionally substituted heterocycl ring;
- R^3 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxy C_{1-6} alkyl, trifluoromethyl, trifluoromethoxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} fluoroalkoxy, $-(CH_2)_pC_{3-6}$ cycloalkyl, $-(CH_2)_pOC_{3-6}$ cycloalkyl, $-COC_{1-6}$ alkyl, $-SO_2C_{1-6}$ alkyl, $-SOC_{1-6}$ alkyl, $-S-C_{1-6}$ alkyl, $-CO_2C_{1-6}$ alkyl, $-CO_2NR^7R^8$, $-SO_2NR^7R^8$, $-(CH_2)_pNR^7R^8$ or $-(CH_2)_pNR^7COR^8$;
- R^4 represents hydrogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} fluoroalkoxy, trifluoromethyl, trifluoromethoxy, halogen, $-OSO_2CF_3$, $-(CH_2)_pC_{3-6}$ cycloalkyl, $-(CH_2)_qOC_{1-6}$ alkyl or $-(CH_2)_pOC_{3-6}$ cycloalkyl;
- R^5 and R^6 each independently represent hydrogen, C_{1-6} alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring;
- R^7 and R^8 each independently represent hydrogen or C_{1-6} alkyl;
- m and n independently represent an integer selected from 1 and 2;
- p independently represents an integer selected from 0, 1, 2 and 3;
- q independently represents an integer selected from 1, 2 and 3;
- or a pharmaceutically acceptable salt or solvate thereof,
- with the proviso that the compounds 8-hydroxy-3-methyl-7-phenylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 8-hydroxy-7-4-(hydroxyphenyl)sulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline and 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline hydrochloride are excluded.
- It is to be understood that the present invention covers all combinations of particular and preferred groups described herein above.

As used herein, the term "alkyl" refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms. For example, C_{1-6} alkyl means a straight

or branched alkyl containing at least 1, and at most 6, carbon atoms. Examples of "alkyl" as used herein include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, isobutyl, isopropyl, t-butyl and 1,1-dimethylpropyl.

- 5 As used herein, the term "alkoxy" refers to a straight or branched alkoxy group containing the specified number of carbon atoms. For example, C₁₋₆alkoxy means a straight or branched alkoxy group containing at least 1, and at most 6, carbon atoms. Examples of "alkoxy" as used herein include, but are not limited to, methoxy, ethoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy, 2-methylprop-1-oxy, 2-methylprop-2-oxy, 2,2,2-trifluoroethoxy, 2,2-dimethylprop-1-oxy, -O-CH₂-c-propyl, pentoxy or hexyloxy.

10 As used herein, the term "C₁₋₆fluoroalkoxy" refers to a straight or branched alkoxy group containing the specified number of carbon atoms wherein any of the carbon atoms may be substituted by one or more fluorine atoms. Examples of "C₁₋₆fluoroalkoxy" as used herein include, but are not limited to, 2,2,2-trifluoroethoxy.

15 As used herein, the term "cycloalkyl" refers to a non-aromatic hydrocarbon ring containing the specified number of carbon atoms. For example, C₃₋₇cycloalkyl means a non-aromatic ring containing at least three, and at most seven, ring carbon atoms. Examples of "cycloalkyl" as used herein include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. A C₆₋₇cycloalkyl group is preferred.

20 As used herein, the term "halogen" refers to the elements fluorine, chlorine, bromine and iodine. Preferred halogens are fluorine, chlorine and bromine.

25 As used herein, the term "aryl" refers to a phenyl or a naphthyl ring.


30 As used herein, the term "heteroaryl" refers to a 5- or 6-membered heterocyclic aromatic ring or a fused bicyclic heteroaromatic ring system.

35 As used herein, the term "heterocycl" refers to a 3- to 7-membered monocyclic saturated ring containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur. Examples of suitable heterocyclic rings include, but are not limited to, piperidine and morpholine.

40 As used herein, the term "5- or 6-membered heterocyclic aromatic ring" refers to a monocyclic unsaturated ring containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur. Examples of suitable 5- and 6-membered heterocyclic aromatic rings include, but are not limited to, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazyl, pyrimidinyl, pyrazolyl, isothiazolyl and isoxazolyl.

- As used herein, the term "fused bicyclic heteroaromatic ring system" refers to a ring system comprising one six-membered unsaturated ring and one 5- or 6-membered unsaturated ring fused together, the ring system containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur. Examples of suitable fused 5 bicyclic heteroaromatic ring systems include, but are not limited to, indolyl, benzofuranyl, quinolyl and benzothienyl.
- As used herein, the term "azacycloalkyl ring" refers to a 4- to 7-membered monocyclic saturated ring containing one nitrogen atom. Examples of suitable azacycloalkyl rings 10 are azetidine, pyrrolidine, piperidine and azepine.
- As used herein, the term "oxo-substituted azacycloalkyl ring" refers to an azacycloalkyl ring as defined above substituted by one oxo group. Examples of suitable oxo-substituted 15 azacycloalkyl rings include, but are not limited to, azetidinone, pyrrolidinone, piperidinone and azepinone.
- As used herein, the term "substituted" refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated.
- 20 As used herein, the term "solvate" refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I) or a salt thereof) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include water, methanol, ethanol and acetic acid. Most preferably the solvent used is water and the solvate may also be referred to as 25 a hydrate.
- It will be appreciated that for use in medicine the salts of formula (I) should be physiologically acceptable. Suitable physiologically acceptable salts will be apparent to those skilled in the art and include for example acid addition salts formed with inorganic 30 acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid; and organic acids e.g. succinic, maleic, malic, mandelic, acetic, fumaric, glutamic, lactic, citric, tartaric, benzoic, benzenesulfonic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid. Other non-physiologically acceptable salts e.g. oxalates, may be used, for example 35 in the isolation of compounds of formula (I) and are included within the scope of this invention. Also included within the scope of the invention are solvates and hydrates of the compounds of formula (I).
- Certain of the compounds of formula (I) may form acid addition salts with one or more equivalents of the acid. The present invention includes within its scope all possible 40 stoichiometric and non-stoichiometric forms thereof.

- Certain compounds of formula (I) may exist in stereoisomeric forms (e.g. they may contain one or more asymmetric carbon atoms). The individual stereoisomers (enantiomers and diastereomers) and mixtures of these are included within the scope of the present invention. The present invention also covers the individual isomers of the compounds represented by formula (I) as mixtures with isomers thereof in which one or more chiral centres are inverted. Likewise, it is understood that compounds of formula (I) may exist in tautomeric forms other than that shown in the formula and these are also included within the scope of the present invention.
- 5 The groups R², R³ and R⁴ may be located on any position on their respective phenyl rings. When R² represents an optionally substituted aryl ring, an optionally substituted heteroaryl ring, or an optionally substituted heterocycl ring, the optional substituents may be selected from C₁₋₆alkyl, C₁₋₆alkoxy, halogen, trifluoromethyl, trifluoromethoxy, cyano and –S-C₁₋₆alkyl.
- 10 Preferably, R¹ represents hydrogen or C₁₋₄alkyl. More preferably, R¹ represents hydrogen, methyl, ethyl, n-propyl or isopropyl. Even more preferably, R¹ represents hydrogen, methyl, ethyl or isopropyl .
- 15 Preferably, R² represents hydrogen, halogen, C₁₋₆alkyl or C₁₋₆alkoxy. More preferably, R² represents hydrogen, halogen, C₁₋₄alkyl or C₁₋₄alkoxy. Even more preferably, R² represents hydrogen, methoxy or bromo.
- 20 In a first embodiment of the invention, the R² group is located at the para-position relative to the group B i.e. a compound of formula (IA)
- 25



- 30 or a pharmaceutically acceptable salt or solvate thereof wherein groups A, B and R¹ to R⁴ have any of the meanings as given hereinbefore.


When R² is located in the para-position i.e. compounds of formula (IA), R² is preferably hydrogen or methoxy.

- 35 For compounds of the formulae (I) or (IA), preferably, when R² represents an optionally substituted aryl ring, an optionally substituted heteroaryl ring, or an optionally substituted heterocycl ring, the optional substituents are independently selected from chlorine, fluorine, bromine, methyl, ethyl, t-butyl, methoxy, trifluoromethyl, trifluoromethoxy, cyano, –S-methyl and –NR⁵R⁶ wherein R⁵ and R⁶ are as hereinbefore described.

For compounds of the formulae (I) or (IA), preferably, R³ represents hydrogen, hydroxy, C₁₋₄alkyl or C₁₋₄alkoxy. More preferably, R³ represents hydrogen, methyl or methoxy. Even more preferably, R³ represents hydrogen, methyl or methoxy.

5

In another embodiment of the invention, the R³ group is located at the ortho-position relative to the sulfone group i.e. a compound of formula (IB)




- 10 or a pharmaceutically acceptable salt or solvate thereof wherein groups A, B and R¹ to R⁴ have any of the meanings as given hereinbefore.

When R³ is located in the ortho-position i.e. compounds of formula (IB), R³ is preferably hydrogen, methyl or methoxy.

15

- For compounds of the formulae (I), (IA) or (IB), preferably, R⁴ represents hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄fluoroalkoxy, trifluoromethyl, trifluoromethoxy, halogen or -OSO₂CF₃. More preferably, R⁴ represents C₁₋₄alkyl or C₁₋₄alkoxy. More preferably, R⁴ represents isopropyl, n-butyl, t-butyl, ethoxy, propoxy, isopropoxy, trifluoromethoxy, -OSO₂CF₃, 2,2,2-trifluoroethoxy, 2,2-dimethylprop-1-oxy, -OCH₂-c-propyl, or pentoxy.

In another embodiment of the invention, the R⁴ group is located at the meta-position relative to the sulfone group i.e. a compound of formula (IC)




- 25 or a pharmaceutically acceptable salt or solvate thereof wherein groups A, B and R¹ to R⁴ have any of the meanings as given hereinbefore.

When R⁴ is located in the meta-position i.e. compounds of formula (IC), R⁴ is preferably C₁₋₄alkyl or C₁₋₄alkoxy.

30

In another embodiment of the invention, the R⁴ group is located at the para-position relative to the sulfone group i.e. a compound of formula (ID)




or a pharmaceutically acceptable salt or solvate thereof wherein groups A, B and R¹ to R⁴ have any of the meanings as given hereinbefore.

5

When R⁴ is located in the para-position i.e. compounds of formula (ID), R⁴ is preferably C₁₋₄alkyl or C₁₋₄alkoxy. More preferably, R⁴ represents isopropyl, n-butyl, t-butyl, ethoxy, propoxy, isopropoxy, trifluoromethoxy, -OSO₂CF₃, 2,2,2-trifluoroethoxy, 2,2-dimethylprop-1-oxy, -OCH₂-c-propyl, or pentoxy.

10

In another embodiment of the invention, the R³ group is located at the ortho-position relative to the sulfone group and the R⁴ group is located at the para-position relative to the sulfone group i.e. a compound of formula (IE)



15

or a pharmaceutically acceptable salt or solvate thereof wherein groups A, B and R¹ to R⁴ have any of the meanings as given hereinbefore.


20
25

For compounds of the formulae (I), (IA), (IB), (IC), (ID) or (IE), preferably, R⁵ and R⁶ independently represent hydrogen or C₁₋₄alkyl. More preferably, R⁵ and R⁶ independently represent hydrogen or methyl.

25

For compounds of the formulae (I), (IA), (IB), (IC), (ID) or (IE), preferably, R⁷ and R⁸ independently represent hydrogen or C₁₋₄alkyl. More preferably, R⁷ and R⁸ independently represent hydrogen or methyl.


For compounds of the formula (I), (IA), (IB), (IC), (ID) or (IE), preferably, p represents 0. In another embodiment of the invention, m is 1 and n is 1 and the invention is a compound of formula (IF):



30


or a pharmaceutically acceptable salt or solvate thereof wherein groups R¹ to R⁴ have any of the meanings as given hereinbefore.

- 5 In another embodiment of the invention, m is 2 and n is 1 and the invention is a compound of formula (IG):




or a pharmaceutically acceptable salt or solvate thereof wherein groups R¹ to R⁴ have any of the meanings as given hereinbefore.

- 10 In another embodiment of the invention, m is 1 and n is 2 and the invention is a compound of formula (IH):




- 15 or a pharmaceutically acceptable salt or solvate thereof wherein groups R¹ to R⁴ have any of the meanings as given hereinbefore.

In another embodiment of the invention, m is 2 and n is 2 and the invention is a compound of formula (IJ):




- 20 or a pharmaceutically acceptable salt or solvate thereof wherein groups R¹ to R⁴ have any of the meanings as given hereinbefore.

25 In another embodiment of the invention, m is 2 and n is 2, the R² group is located at the para-position relative to the group B, the R³ group is located at the ortho-position relative to the sulfone group, the R⁴ group is located at the meta-position relative to the sulfone group and the invention is a compound of formula (IK):



or a pharmaceutically acceptable salt or solvate thereof wherein groups R¹ to R⁴ have any of the meanings as given hereinbefore.

- 5 In another embodiment of the invention, m is 2 and n is 2, the R² group is located at the para-position relative to the group B, the R³ group is located at the ortho-position relative to the sulfone group, the R⁴ group is located at the para-position relative to the sulfone group and the invention is a compound of formula (IL):



- 10 or a pharmaceutically acceptable salt or solvate thereof wherein groups R¹ to R⁴ have any of the meanings as given hereinbefore.


Particular compounds according to the invention include those incorporated in Tables 1
15 and 2 and those specifically exemplified and named hereinafter including, without limitation:-

7-(4-n-butylphenylsulfonyl)-1,2,3,5-tetrahydro-3-benzazepine; and
7-(4-n-butylphenylsulfonyl)-3-methyl-1,2,3,5-tetrahydro-3-benzazepine.


- 20 The compounds of the present invention may be in the form of their free base or physiologically acceptable salts thereof, particularly the monohydrochloride or monomesylate salts or pharmaceutically acceptable derivatives thereof.

- 25 The present invention also provides a general process (A) for preparing compounds of formula (I) which process comprises:

reacting a compound of formula (II)



- 30 with a compound of formula (III)



wherein L is a leaving group, such as fluoro, chloro, alkoxy or aryloxy, M is a metal, such as lithium or magnesium, R'¹-R'⁴ represent R¹ to R⁴ as hereinbefore defined or are groups that may be readily convertible to R¹ to R⁴, and A and B are as hereinbefore defined.

5


This general method (A) can be conveniently performed by mixing the two components at preferably -70°C to room temperature in a suitable solvent such as tetrahydrofuran or ether for 10 minutes to 18 hours. Removal of certain R'¹ protecting groups e.g. trifluoroacetyl, can also take place simultaneously during this process.

10


The present invention also provides a general process (B) for preparing compounds of formula (I), which process comprises:

reacting a compound of formula (IV)

15



with an alkyl boronic acid of formula (V)



20

wherein X is a leaving group, such as bromo, iodo, chloro, triflate or N₂⁺, A and B are as hereinbefore defined and R'¹-R'⁴ represent R¹ to R⁴ as hereinbefore defined or are groups that may be readily convertible to R¹ to R⁴. This general method (B) can be conveniently performed by mixing the two components in a suitable solvent such as toluene or ethanol


25

containing aqueous sodium carbonate and a catalytic amount of Pd(PPh₃)₄ at room temperature or reflux under argon.


The present invention also provides a general process (C) for preparing compounds of formula (I) which process comprises:

30

reacting a compound of formula (VI)



with a compound of formula (VII)




5


wherein L is a leaving group, such as fluoro, chloro, alkoxy or aryloxy, M is a metal, such as lithium or magnesium, A and B are as hereinbefore defined and R¹-R⁴ represent R¹ to R⁴ as hereinbefore defined or are groups that may be readily convertible to R¹ to R⁴. This
 10 general method (C) can be conveniently performed by mixing the two components at preferably -70°C to room temperature in a suitable solvent such as tetrahydrofuran or ether for 10 minutes to 18 hours.

The present invention also provides a general process (D) for preparing compounds of
 15 formula (I) which process comprises:

reacting a reagent of formula (VIII)



20 with a compound of formula (IX)




wherein L is a leaving group, such as fluoro, chloro or triflate, A and B are as hereinbefore defined and R¹-R⁴ represent R¹ to R⁴ as hereinbefore defined or are groups that may be readily convertible to R¹ to R⁴. This general method (D) can be conveniently performed by mixing the two components in a suitable solvent such as dimethylformamide in the presence of copper iodide at elevated temperature e.g. 120°C.
 25


The present invention also provides a general process (E) for preparing compounds of formula (I) which process comprises:

reacting a reagent of formula (X)

5



with a compound of formula (IX)



10

followed by the oxidation of the resultant sulfide, by for example, meta-chloroperbenzoic acid, wherein L is a leaving group, such as fluoro, chloro, triflate or N_2^+ , A and B are as hereinbefore defined and $R^1\text{-}R^4$ represent R^1 to R^4 as hereinbefore defined or are groups that may be readily convertible to R^1 to R^4 . This general method (E) can be conveniently 15 performed by mixing the two components in a suitable solvent such as dimethylformamide, optionally at elevated temperature e.g. 120°C.

Interconversion of one of the R^1 to R^5 groups to the corresponding R^1 to R^4 groups typically arises when one compound of formula (I) is used as the immediate precursor of 20 another compound of formula (I), or when it is easier to introduce a more complex or reactive substituent at the end of a synthetic sequence.

For example, conversion of R^1 from a t-butoxycarbonyl (BOC) group to hydrogen is conducted by the treatment of the N-BOC protected compound with hydrogen chloride in 25 ethanol or dioxan at room temperature.

Conversion of R^1 from hydrogen to an alkyl group is conducted by the treatment of the NH compound with the appropriate aldehyde in dichloroethane in the presence of a reducing agent, such as sodium triacetoxyborohydride, or by the treatment of the NH 30 compound with the appropriate alkyl halide, such as iodomethane, under standard alkylation conditions (potassium carbonate in DMF at 60°C).

Compounds of formula (II) are known in the literature or may be prepared by known processes, for example, chlorosulfonation of the aromatic ring using chlorosulfonic acid. 35 Conversion to the sulfonyl fluoride can be achieved, if required, by reaction with potassium fluoride in acetonitrile at room temperature. Suitable examples of an R^1 protecting group are trifluoroacetyl or the t-butoxycarbonyl (BOC) group.

Compounds of formula (III) are commercially available or may be prepared by established procedures, for example lithiation of the corresponding bromobenzene in tetrahydrofuran at low temperature, with for example t-butyl lithium.

5

Compounds of formula (IV) may be prepared using a similar process to general process A.

10 Compounds of formula (V) are commercially available, or may be prepared by lithiation of the corresponding bromo aromatic compound, followed by quenching with tri-isopropyl borate then hydrolysis.

Compounds of formula (VI) may be prepared by metal halogen exchange using the corresponding bromo analogue as starting material and t-butyl lithium at low temperature.

15 Compounds of formula (VII) are commercially available or may be prepared by chlorosulfonylation of the aromatic ring. Conversion to the sulfonyl fluoride can be achieved, if required, by reaction with potassium fluoride in acetonitrile at room temperature.

20 Compounds of formula (VIII) may be prepared by reduction of the corresponding sulfonyl chloride, using for example sodium bisulphite and sodium bicarbonate in tetrahydrofuran/water. Deprotonation of the sulfonic acid can be achieved by treatment with base, e.g. sodium hydride.

25 Compounds of formula (IX) are commercially available or may be prepared using standard literature methodology.

Compounds of formula (X) may be prepared by reduction of compounds of formula (II) using for example lithium aluminium hydride in tetrahydrofuran. Deprotonation of the thiol 30 can be achieved by treatment with base, e.g. sodium hydride.

Compounds of formula (I) have antagonist affinity for the serotonin 5-HT_{2C}, 5-HT_{2A} and 5-HT₆ receptors. These properties may give rise to anti-psychotic activity (e.g. improved effects on cognitive dysfunction) activity with reduced extrapyramidal side effects (eps), 35 and/or anxiolytic/antidepressant activity. These could include, but are not limited to, attenuation of cognitive symptoms via 5-HT₆ receptor blockade (see Reavill, C. and Rogers, D.C., 2001, Investigational Drugs 2, 104-109), and reduced anxiety (see for example Kennett et al., Neuropharmacology 1997 Apr-May; 36 (4-5): 609-20), protection against EPS (Reavill et al., Brit. J. Pharmacol., 1999; 126: 572-574) and antidepressant 40 activity (Bristow et al., Neuropharmacology 39:2000; 1222-1236) via 5-HT_{2c} receptor blockade.

Certain compounds of formula (I) have also been found to exhibit affinity for dopamine receptors, in particular the D₃ and D₂ receptors, and are useful in the treatment of disease states which require modulation of such receptors, such as psychotic conditions.

Many of the compounds of formula (I) have also been found to have greater affinity for dopamine D₃ than for D₂ receptors. The therapeutic effect of currently available antipsychotic agents (neuroleptics) is generally believed to be exerted via blockade of D₂ receptors; however this mechanism is also thought to be responsible for undesirable eps associated with many neuroleptic agents. Without wishing to be bound by theory, it has been suggested that blockade of the dopamine D₃ receptor may give rise to beneficial antipsychotic activity without significant eps (see for example Sokoloff et al, Nature, 1990; 347: 146-151; and Schwartz et al, Clinical Neuropharmacology, Vol 16, No. 4, 295-314, 1993).

Compounds of formula (I) may also exhibit affinity for other receptors not mentioned above, resulting in beneficial antipsychotic activity.

The compounds of formula (I) are of use as antipsychotic agents for example in the treatment of schizophrenia, schizo-affective disorders, schizophreniform diseases, psychotic depression, mania, acute mania, paranoid and delusional disorders.

Furthermore, they may have utility as adjunct therapy in Parkinsons Disease, particularly with compounds such as L-DOPA and possibly dopaminergic agonists, to reduce the side effects experienced with these treatments on long term use (e.g. see Schwartz et al., Brain Res. Reviews, 1998, 26, 236-242). From the localisation of D₃ receptors, it could also be envisaged that the compounds could also have utility for the treatment of substance abuse where it has been suggested that D₃ receptors are involved (e.g. see Levant, 1997, Pharmacol. Rev., 49, 231-252). Examples of such substance abuse include alcohol, cocaine, heroin and nicotine abuse. Other conditions which may be treated by the compounds include dyskinetic disorders such as Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias; depression; anxiety; agitation; tension; social or emotional withdrawal in psychotic patients; cognitive impairment including memory disorders such as Alzheimer's disease; psychotic states associated with neurodegenerative disorders, e.g. Alzheimer's disease; eating disorders; obesity; sexual dysfunction; sleep disorders; emesis; movement disorders; obsessive-compulsive disorders; amnesia; aggression; autism; vertigo; dementia; circadian rhythm disorders; and gastric motility disorders e.g. IBS.

Therefore, the invention provides a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof for use in therapy.

The invention also provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of a condition which requires modulation of a dopamine receptor.

- The invention also provides a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of psychotic disorders, schizophrenia, Parkinsons disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders.
- 10 The invention also provides the use of a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of a condition which requires modulation of a dopamine receptor.
- 15 The invention also provides the use of a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of psychotic disorders, schizophrenia, Parkinsons disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, 20 movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders.
- The invention also provides a method of treating a condition which requires modulation of a dopamine receptor, which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof.
- 25 The invention also provides a method of treating psychotic disorders, schizophrenia, Parkinsons disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof.
- 30 The invention also provides a method of treating psychotic disorders, schizophrenia, Parkinsons disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a pharmaceutically acceptable salt or solvate thereof.
- 35 A preferred use for dopamine antagonists according to the present invention is in the treatment of psychotic disorders, schizophrenia, Parkinsons disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety and cognitive impairment.
- 40 "Treatment" includes prophylaxis, where this is appropriate for the relevant condition(s).

It will be appreciated by those skilled in the art that the compounds according to the invention may advantageously be used in conjunction with one or more other therapeutic agents, for instance, different antidepressant agents such as 5HT₃ antagonists, serotonin agonists, NK-1 antagonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline 5
re-uptake inhibitors (SNRI), tricyclic antidepressants, dopaminergic antidepressants, H₃ antagonists, 5HT_{1A} antagonists, 5HT_{1B} antagonists, 5HT_{1D} antagonists, D₁ agonists, M₁ agonists and/or anticonvulsant agents.

10 Suitable 5HT₃ antagonists which may be used in combination of the compounds of the inventions include for example ondansetron, granisetron, metoclopramide.

Suitable serotonin agonists which may be used in combination with the compounds of the invention include sumatriptan, rauwolscine, yohimbine, metoclopramide.

15 Suitable SSRIs which may be used in combination with the compounds of the invention include fluoxetine, citalopram, femoxetine, fluvoxamine, paroxetine, indalpine, sertraline, zimeldine.

20 Suitable SNRIs which may be used in combination with the compounds of the invention include venlafaxine and reboxetine.

Suitable tricyclic antidepressants which may be used in combination with a compound of the invention include imipramine, amitriptyline, chlomipramine and nortriptyline.

25 Suitable dopaminergic antidepressants which may be used in combination with a compound of the invention include bupropion and aminextine.

Suitable anticonvulsant agents which may be used in combination of the compounds of the inventions include for example divalproex, carbamazepine and diazepam.

30 It will be appreciated that the compounds of the combination or composition may be administered simultaneously (either in the same or different pharmaceutical formulations), separately or sequentially.

35 For use in medicine, the compounds of the present invention are usually administered as a standard pharmaceutical composition. The present invention therefore provides in a further aspect a pharmaceutical composition comprising a compound of formula (I) as hereinbefore described or a pharmaceutically (i.e. physiologically) acceptable salt thereof and a pharmaceutically (i.e. physiologically) acceptable carrier. The pharmaceutical composition can be for use in the treatment of any of the conditions described herein.

40

The compounds of formula (I) may be administered by any convenient method, for example by oral, parenteral (e.g. intravenous), buccal, sublingual, nasal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly.

- 5 The compounds of formula (I) as hereinbefore described and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.

A liquid formulation will generally consist of a suspension or solution of the compound or
10 pharmaceutically acceptable salt in a suitable liquid carrier(s) for example an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil. The formulation may also contain a suspending agent, preservative, flavouring or colouring agent.

15 A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.

A composition in the form of a capsule can be prepared using routine encapsulation
20 procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.

25 Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent
30 just prior to administration.

Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders. Aerosol formulations typically comprise a solution or fine suspension of the active substance in a pharmaceutically acceptable aqueous or non-aqueous solvent
35 and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device. Alternatively the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal once the contents of the container have been exhausted. Where the dosage
40 form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas such as compressed air or an organic propellant such as a fluorochloro-hydrocarbon. The aerosol dosage forms can also take the form of a pump-atomiser.

Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.

5 Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.

10 Compositions suitable for transdermal administration include ointments, gels and patches. Preferably the composition is in unit dose form such as a tablet, capsule or ampoule.

Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.

15 The pharmaceutically acceptable compounds of the invention will normally be administered in a daily dosage regimen (for an adult patient) of, for example, an oral dose of between 1 mg and 500 mg, preferably between 10 mg and 400 mg, e.g. between 10 and 250 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg
20 and 100 mg, preferably between 0.1 mg and 50 mg, e.g. between 1 and 25 mg of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day. Suitably the compounds will be administered for a period of continuous therapy, for example for a week or more.

25 No toxicological effects are indicated/expected when a compound of the invention is administered in the above mentioned dosage range.

Biological Test Methods

30 Binding experiments on cloned dopamine (e.g. D2 and D3) receptors

The ability of the compounds to bind selectively to human D2/D3 dopamine receptors can be demonstrated by measuring their binding to cloned receptors. The inhibition constants (K_i) of test compounds for displacement of [125 I]-Iodosulpride binding to human D2/D3 receptors expressed in CHO cells were determined as follows. The cell lines were shown to be free from bacterial, fungal and mycoplasmal contaminants, and stocks of each were stored frozen in liquid nitrogen. Cultures were grown as monolayers or in suspension in standard cell culture media. Cells were recovered by scraping (from monolayers) or by centrifugation (from suspension cultures), and were washed two or three times by suspension in phosphate buffered saline followed by collection by centrifugation. Cell pellets were stored frozen at -80°C. Crude cell membranes were prepared by homogenisation followed by high-speed centrifugation, and characterisation of cloned receptors achieved by radioligand binding.

- Preparation of CHO cell membranes: Cell pellets were gently thawed at room temperature, and resuspended in about 20 volumes of ice-cold Extraction buffer; 5mM EDTA, 50mM Trizma pre-set crystals (pH7.4@37°C), 1mM MgCl₂, 5mM KCl and 120mM NaCl. The suspension was homogenised using an Ultra-Turrax at full speed for 15 seconds. The homogenate was centrifuged at 18,000 r.p.m. for 15 min at 4°C in a Sorvall RC5C centrifuge. Supernatant was discarded, and homogenate re-suspended in extraction buffer then centrifugation was repeated. The final pellet was resuspended in 50mM Trizma pre-set crystals (pH 7.4 @ 37°C) and stored in 1ml aliquot tubes at -80°C (D2 = 3.0E+08 cells, D3 = 7.0E+07 cells and D4 = 1.0E+08 cells). The protein content was determined using a BCA protocol and bovine serum albumin as a standard (Smith, P. K., et al., Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85 (1985)).
- 15 Binding experiments: Crude D2/D3 cell membranes were incubated with 0.03nM [¹²⁵I]-Iodosulpride (~2000 Ci/mmol; Amersham, U. K., and the test compound in a buffer containing 50mM Trizma pre-set crystals (pH 7.4 @ 37°C), 120mM NaCl, 5mM KCl, 2mM CaCl₂, 1mM MgCl₂, 0.3% (w/v) bovine serum albumin. The total volume is 0.2ml and incubated in a water bath at 37°C for 40 minutes. Following incubation, samples were 20 filtered onto GF/B Unifilters using a Canberra Packard Filtermate, and washed four times with ice-cold 50mM Trizma pre-set crystals (pH 7.4 @ 37°C). The radioactivity on the filters was measured using a Canberra Packard Topcount Scintillation counter. Non-specific binding was defined with 10μM SKF-102161 (YM-09151). For competition curves, 10 serial log concentrations of competing cold drug were used (Dilution range: 25 10μM-10pM). Competition curves were analysed using Inflexion, an iterative curve fitting programme in Excel. Results were expressed as pK_i values where pK_i = -log₁₀[K_i].
- The exemplified compounds have pK_i values within the range of 5.8 – 8.2 at the 30 dopamine D₃ receptor.
- The exemplified compounds have pK_i values within the range of 5.3 – 7.7 at the dopamine D₂ receptor.
- 35 Binding experiments on cloned 5-HT₆ receptors
Compounds can be tested following the procedures outlined in WO 98/27081.
- The exemplified compounds have pK_i values within the range of 7.2 – 8.9 at the serotonin 40 5-HT₆ receptor.
- Binding experiments on cloned 5-HT_{2A} and 5-HT_{2C} receptors
Compounds can be tested following the procedures outlined in WO 94/04533.


The exemplified compounds have pK_i values within the range of 7.1 – 9.7 at the serotonin 5-HT_{2C} receptor and of 7.0 – 10.0 at the serotonin 5-HT_{2A} receptor.

- 5 The invention is further illustrated by the following non-limiting examples:

Description 1

3-Trifluoroacetyl-1,2,4,5-tetrahydro-3-benzazepine-7-sulfonyl fluoride (D1)

10



a) 3-Trifluoroacetyl-1,2,4,5-tetrahydro-3-benzazepine-7-sulfonyl chloride


A solution of 3-trifluoroacetyl-1,2,4,5-tetrahydro-3-benzazepine (20g, 80mmol) in dichloromethane (50ml) was added dropwise to a solution of chlorosulfonic acid (33ml, 240mmol) in more dichloromethane (200ml) at 0°C. The resulting solution was stirred for 18h without cooling then poured onto ice (250g). The resulting organic layer was washed with brine (100ml), dried ($MgSO_4$), and evaporated to give the subtitle compound as a white solid (23g).

20 **b) 3-Trifluoroacetyl-1,2,4,5-tetrahydro-3-benzazepine-7-sulfonyl fluoride**

A mixture of 3-trifluoroacetyl-1,2,4,5-tetrahydro-3-benzazepine-7-sulfonyl chloride (23g, 67mmol), potassium fluoride (12g, 200mmol), 18-crown-6 (0.1g), and acetonitrile (100ml) was stirred overnight. Water (200ml) and ethyl acetate (200ml) were added and the organic layer was washed with brine (100ml), dried ($MgSO_4$), and evaporated to give the title compound as a white solid (21g). ¹H NMR δ (d₆-DMSO) 3.2 (4H, m), 3.7 (4H, m), 7.6 (1H, m), and 8.0 (2H, m).

Description 2

3-Trifluoroacetyl-8-methoxy-1,2,4,5-tetrahydro-3-benzazepine-7-sulfonyl fluoride (D2)



a) 3-Trifluoroacetyl-8-methoxy-1,2,4,5-tetrahydro-3-benzazepine

To a mixture of 8-methoxy-1,2,4,5-tetrahydro-3-benzazepine hydrochloride (5.1g, 25 mmol), triethylamine (8.4ml, 60mmol), and dichloromethane (100ml) at 0°C, was added

dropwise trifluoroacetic anhydride (3.5ml, 26mmol). The solution was stirred for 2h without cooling then washed with saturated aqueous sodium hydrogen carbonate(100ml), and water (100ml), dried (MgSO_4), and evaporated to give the title compound as a white solid (5.5g).

5

b) 3-Trifluoroacetyl-8-methoxy-1,2,4,5-tetrahydro-3-benzazepine-7-sulfonyl chloride

Prepared from 3-trifluoroacetyl-8-methoxy-1,2,4,5-tetrahydro-3-benzazepine using the method of Description 1(a); yield 85%.

10 **c) 3-Trifluoroacetyl-8-methoxy-1,2,4,5-tetrahydro-3-benzazepine-7-sulfonyl fluoride**


Prepared from 3-trifluoroacetyl-8-methoxy-1,2,4,5-tetrahydro-3-benzazepine-7-sulfonyl chloride using the method of Description 1(b); yield 80%.

^1H NMR δ (d_6 -DMSO) 3.1 (4H, m), 3.7 (4H, m), 4.0 (3H, s), 7.3 (1H, 2s, rotamers), and 7.8 (1H, 2s, rotamers).

15

Example 1

7-(4-n-Butylphenylsulfonyl)-1,2,4,5-tetrahydro-3-benzazepine (E1)



20


A solution of 4-n-butylbromobenzene (4.7g, 22mmol) in THF (35ml) at -70°C was treated with tert-butyllithium (25ml, 1.7M in pentane, 42mmol). After 20min at -70°C, a solution of D1 (2.7g, 7.5mmol) in more THF (10ml) was added, and after a further 30min stirring without cooling, water (100ml) and ethyl acetate (100ml) were added. The organic layer

25 was washed with brine (100ml), dried (MgSO_4), and evaporated. Chromatography on silica, eluting with 0 to 15% methanol in dichloromethane containing 0.1M ammonia, gave the title compound, isolated as the hydrochloride salt from ether (1.6g). MH^+ 344. ^1H NMR δ (d_6 -DMSO) 0.9 (3H, t, $J=7\text{Hz}$), 1.3 (2H, m), 1.5 (2H, m), 2.6 (2H, t, $J=8\text{Hz}$), 3.2 (8H, m), 7.4 (3H, m), 7.8 (4H, m), and 9.3 (2H, bs).

30

Example 2

7-(4-n-Butylphenylsulfonyl)-3-methyl-1,2,4,5-tetrahydro-3-benzazepine (E2)



35


A mixture of E1 hydrochloride salt (1.6g, 4.7mmol), sodium triacetoxyborohydride (5.0g), aqueous formaldehyde (5.0ml, 37%), and 1,2-dichloroethane (100ml) was stirred for 18h then diluted with dichloromethane (50ml) and washed with saturated aqueous sodium hydrogen carbonate (100ml), dried (MgSO_4), and evaporated to give the title compound
 5 isolated as the hydrochloride salt from ether (1.3g). MH^+ 358. $^1\text{H NMR}$ δ (d_6 -DMSO) 0.9 (3H, t $J=7\text{Hz}$), 1.3 (2H, m), 1.5 (2H, m), 2.6 (2H, t, $J=8\text{Hz}$), 2.8 (3H, d, $J=5\text{Hz}$), 2.9-3.6 (8H, m), 7.4 (3H, m), 7.8 (4H, m), and 11.1 (1H, bs).

Examples 3-47 were prepared using analogous procedures to Examples 1 and 2.
 10 Products were isolated as either the free bases or hydrochloride salts. All $^1\text{H NMR}$ are consistent with the structures shown.

All of the compounds listed below in Table 1 relate to compounds of formula (I), (IA), (IB), (ID), (IE), (IJ) and (IL) wherein m and n both are 2-:

15

Table 1




Example	R ¹	R ²	R ³	R ⁴	MH ⁺
1	H	H	H	nBu	344
2	Me	H	H	nBu	358
3	H	OMe	H	nBu	374
4	Me	OMe	H	nBu	388
5	H	H	H	tBu	344
6	Me	H	H	tBu	358
7	H	H	H	iPr	330
8	Me	H	H	iPr	344
9	Et	OMe	H	nBu	402
10	Me	OMe	H	iPr	374
11	H	OMe	H	iPr	360
12	H	OMe	H	tBu	374
13	Me	OMe	H	tBu	388
14	H	OH	H	nBu	360
28	H	H	H	OCF ₃	372
29	Me	H	H	OCF ₃	386
30	H	H	H	OnPr	346
31	H	H	H	OSO ₂ CF ₃	436
32	Me	H	H	OnPr	360

Example	R ¹	R ²	R ³	R ⁴	MH ⁺
33	H	OMe	H	OCF ₃	402
34	Me	OMe	H	OCF ₃	416
35	H	OMe	H	OnPr	376
36	Me	OMe	H	OnPr	390
48	Me	OMe	H	OEt	376
49	Me	OMe	H	OCH ₂ CF ₃	430
50	Me	OMe	H	O-iPr	390
51	Me	OMe	H	OCH ₂ -tBu	418
52	Me	OMe	H	OCH ₂ -c-propyl	402
53	Me	OMe	H	O-c-pentyl	416
54	Me	OMe	Me	OnPr	404

All of the compounds listed below in Table 2 relate to compounds of formula (I), (IA), (IB), (IC), (IJ) and (IK) wherein m and n both are 2:-

5

Table 2



Example	R ¹	R ²	R ³	R ⁴	MH ⁺
15	H	H	H	nBu	344
16	Me	H	H	nBu	358
17	H	OMe	H	nBu	374
18	Me	OMe	H	nBu	388
19	iPr	OMe	H	nBu	416
20	H	H	H	iPr	330
21	Me	H	H	iPr	344
22	H	OMe	H	iPr	360
23	Me	OMe	H	iPr	374
24	H	H	OMe	nBu	374
25	Me	H	OMe	nBu	388
26	Me	H	OH	nBu	374
27	H	H	H	OH	304
37	H	H	H	OCF ₃	372
38	H	H	H	OiPr	346


Example	R ¹	R ²	R ³	R ⁴	MH ⁺
39	Me	H	H	OCF ₃	386
40	Me	H	H	OiPr	360
41	H	H	H	OH	304
42	H	OMe	H	OCF ₃	402
43	H	OMe	H	OiPr	376
44	Me	OMe	H	OCF ₃	416
45	Me	OMe	H	OiPr	390
46	Me	H	H	OnPr	360
47	Me	OMe	H	OnPr	390

All publications, including but not limited to patents and patent applications, cited in this
5 specification are herein incorporated by reference as if each individual publication were
specifically and individually indicated to be incorporated by reference herein as though
fully set forth.

CLAIMS

1. A compound of formula (I):

5



wherein

A and B represent the groups $-(CH_2)_m-$ and $-(CH_2)_n-$ respectively;10 R¹ represents hydrogen or C₁₋₆alkyl;R² represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC₁₋₆alkyl, trifluoromethyl, trifluoromethoxy, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆fluoroalkoxy, -(CH₂)_pC₃₋₆cycloalkyl, -(CH₂)_pOC₃₋₆cycloalkyl, -COC₁₋₆alkyl, -SO₂C₁₋₆alkyl, -SOC₁₋₆alkyl, -S-C₁₋₆alkyl, -CO₂C₁₋₆alkyl, -CO₂NR⁵R⁶, -SO₂NR⁵R⁶, -(CH₂)_pNR⁵R⁶, -(CH₂)_pNR⁵COR⁶, optionally substituted aryl ring,

15 optionally substituted heteroaryl ring or optionally substituted heterocyclil ring;

R³ represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC₁₋₆alkyl, trifluoromethyl, trifluoromethoxy, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆fluoroalkoxy, -(CH₂)_pC₃₋₆cycloalkyl, -(CH₂)_pOC₃₋₆cycloalkyl, -COC₁₋₆alkyl, -SO₂C₁₋₆alkyl, -SOC₁₋₆alkyl, -S-C₁₋₆alkyl, -CO₂C₁₋₆alkyl, -CO₂NR⁷R⁸, -SO₂NR⁷R⁸, -(CH₂)_pNR⁷R⁸ or -(CH₂)_pNR⁷COR⁸;20 R⁴ represents hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆fluoroalkoxy, trifluoromethyl, trifluoromethoxy, halogen, -OSO₂CF₃, -(CH₂)_pC₃₋₆cycloalkyl, -(CH₂)_qOC₁₋₆alkyl or -(CH₂)_pOC₃₋₆cycloalkyl;R⁵ and R⁶ each independently represent hydrogen, C₁₋₆alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring;25 R⁷ and R⁸ each independently represent hydrogen or C₁₋₆alkyl;

m and n independently represent an integer selected from 1 and 2;

p independently represents an integer selected from 0, 1, 2 and 3;

q independently represents an integer selected from 1, 2 and 3;

30 or a pharmaceutically acceptable salt or solvate thereof,

with the proviso that the compounds 8-hydroxy-3-methyl-7-phenylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 8-hydroxy-7-4-(hydroxyphenyl)sulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline and 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline hydrochloride are excluded.

35

2. A compound of formula (I) which is

7-(4-n-butylphenylsulfonyl)-1,2,3,5-tetrahydro-3-benzazepine; and

7-(4-n-butylphenylsulfonyl)-3-methyl-1,2,3,5-tetrahydro-3-benzazepine.

3. A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier therefor.
- 5 4. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in claim 1 or claim 2 for use in therapy with the proviso that the compounds 8-hydroxy-3-methyl-7-phenylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 8-hydroxy-7-4-(hydroxyphenyl)sulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline and 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline hydrochloride are excluded.
10
- 15 5. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in claim 1 or claim 2 for use in the treatment of a condition which requires modulation of a dopamine receptor.
- 20 6. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in claim 1 or claim 2 for use in the treatment of psychotic disorders, Parkinsons disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders with the proviso that the compounds 8-hydroxy-3-methyl-7-phenylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 8-hydroxy-7-4-(hydroxyphenyl)sulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline and 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline hydrochloride are excluded.
25
- 30 7. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in claim 1 or claim 2 in the manufacture of a medicament for the treatment of a condition which requires modulation of a dopamine receptor.
- 35 8. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in claim 1 or claim 2 in the manufacture of a medicament for the treatment of psychotic disorders, Parkinsons disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders with the proviso that the compounds 8-hydroxy-3-methyl-7-phenylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 8-hydroxy-7-4-(hydroxyphenyl)sulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline and 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline hydrochloride are excluded.
40

9. A method of treating a condition which requires modulation of a dopamine receptor, which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in claim 1 or claim 2.

5

10. A method of treating psychotic disorders, Parkinsons disease, substance abuse, dyskinetic disorders, depression, bipolar disorder, anxiety, cognitive impairment, eating disorders, obesity, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders and gastric motility disorders, which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in claim 1 or claim 2 with the proviso that the compounds 8-hydroxy-3-methyl-7-phenylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 8-hydroxy-7-4-(hydroxyphenyl)sulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline and 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline hydrochloride are excluded.

20


25

PATENT COOPERATION TREATY

PCT

4/12

PTO



INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference DMK/P33046	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/EP 03/05728	International filing date (day/month/year) 28/05/2003	(Earliest) Priority Date (day/month/year) 29/05/2002
Applicant GLAXO GROUP LIMITED		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of **05** sheets.

It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
 - the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
- b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing :
 - contained in the international application in written form.
 - filed together with the international application in computer readable form.
 - furnished subsequently to this Authority in written form.
 - furnished subsequently to this Authority in computer readable form.
 - the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
 - the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. Certain claims were found unsearchable (See Box I).

3. Unity of Invention is lacking (see Box II).

4. With regard to the title,

- the text is approved as submitted by the applicant.
- the text has been established by this Authority to read as follows:

7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS

5. With regard to the abstract,

- the text is approved as submitted by the applicant.
- the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No.

- as suggested by the applicant.
- because the applicant failed to suggest a figure.
- because this figure better characterizes the invention.

None of the figures.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 03/05728

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 7	C07D223/16	A61K31/55	A61P25/18	C07D209/44	C07D217/02
		C07D217/04			

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data, BEILSTEIN Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	EP 0 285 287 A (SMITHKLINE BECKMAN CORP) 5 October 1988 (1988-10-05) cited in the application claim 1; examples 9,10 ---	1-10 -/-

Further documents are listed in the continuation of box C

Patent family members are listed in annex

* Special categories of cited documents

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

13 October 2003

Date of mailing of the international search report

20/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax. (+31-70) 340-3016

Authorized officer

Seymour, L

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/05728

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
A	GRUNEWALD G L ET AL: "Synthesis, biochemical evaluation, and classical and three-dimensional quantitative structure-activity relationship studies of 7-substituted-1,2,3,4-tetrahydroisoquinolines and their relative affinities toward phenylethanolamine N-methyltransferase and the alpha2-adrenoceptor" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 42, no. 1, 1999, pages 118-134, XP000971792 ISSN: 0022-2623 cited in the application table 2, compound 21 page 130, paragraph 21.HCL	1
X	WO 02 40471 A (STEMP GEOFFREY ;HADLEY MICHAEL STEWART (GB); LIGHTFOOT ANDREW P (G) 23 May 2002 (2002-05-23) cited in the application page 19, line 28 - line 32 page 35, line 38 -page 36, line 4 page 40, line 16 - line 24 page 44, line 66 - line 68 A page 23, line 9 - line 24	3,5,7,9
X	DE 100 53 799 A (BAYER AG) 8 May 2002 (2002-05-08) page 3, paragraph 24; claim 1; examples 7,13,21	1
A		5,7,9
A		1-10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/05728

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 9 and 10 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows.

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP 03/05728

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
EP 0285287	A	05-10-1988	EP JP	0285287 A2 63255226 A		05-10-1988 21-10-1988
WO 0240471	A	23-05-2002	AU CA WO EP NO	2303402 A 2428844 A1 0240471 A2 1335915 A2 20032161 A		27-05-2002 23-05-2002 23-05-2002 20-08-2003 11-07-2003
DE 10053799	A	08-05-2002	DE	10053799 A1		08-05-2002

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.